Nothing Special   »   [go: up one dir, main page]

MX366159B - Self-regulated release of active pharmaceutical ingredient. - Google Patents

Self-regulated release of active pharmaceutical ingredient.

Info

Publication number
MX366159B
MX366159B MX2015006613A MX2015006613A MX366159B MX 366159 B MX366159 B MX 366159B MX 2015006613 A MX2015006613 A MX 2015006613A MX 2015006613 A MX2015006613 A MX 2015006613A MX 366159 B MX366159 B MX 366159B
Authority
MX
Mexico
Prior art keywords
ingredient
active pharmaceutical
self
pharmaceutical ingredient
regulated release
Prior art date
Application number
MX2015006613A
Other languages
Spanish (es)
Other versions
MX2015006613A (en
Inventor
W Brzeczko Albert
Gary Hollenbeck R
Original Assignee
Acura Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acura Pharmaceuticals Inc filed Critical Acura Pharmaceuticals Inc
Publication of MX2015006613A publication Critical patent/MX2015006613A/en
Publication of MX366159B publication Critical patent/MX366159B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
MX2015006613A 2012-11-30 2013-11-27 Self-regulated release of active pharmaceutical ingredient. MX366159B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731901P 2012-11-30 2012-11-30
PCT/US2013/072249 WO2014085599A1 (en) 2012-11-30 2013-11-27 Self-regulated release of active pharmaceutical ingredient

Publications (2)

Publication Number Publication Date
MX2015006613A MX2015006613A (en) 2015-11-16
MX366159B true MX366159B (en) 2019-07-01

Family

ID=50826034

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006613A MX366159B (en) 2012-11-30 2013-11-27 Self-regulated release of active pharmaceutical ingredient.
MX2019007956A MX2019007956A (en) 2012-11-30 2015-05-26 Self-regulated release of active pharmaceutical ingredient.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019007956A MX2019007956A (en) 2012-11-30 2015-05-26 Self-regulated release of active pharmaceutical ingredient.

Country Status (11)

Country Link
US (8) US9101636B2 (en)
EP (2) EP3446685A1 (en)
JP (7) JP5922851B2 (en)
CN (3) CN108743549B (en)
AU (4) AU2013352162B2 (en)
CA (1) CA2892908C (en)
ES (1) ES2691982T3 (en)
IL (1) IL238713A0 (en)
MX (2) MX366159B (en)
RU (2) RU2673818C2 (en)
WO (1) WO2014085599A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
MX366159B (en) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Self-regulated release of active pharmaceutical ingredient.
ES2764445T3 (en) * 2013-03-15 2020-06-03 Inspirion Delivery Sciences Llc Pharmaceutical products comprising a pH dependent component and a pH increasing agent
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
US9616029B2 (en) * 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
CN106456579B (en) 2014-06-09 2020-04-28 阿库拉制药公司 Methods and compositions for interfering with the extraction or transformation of drugs susceptible to abuse
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
JP6544749B2 (en) * 2014-07-15 2019-07-17 オディディ，イサ Compositions and methods for reducing overdose
CA2955477A1 (en) * 2014-09-27 2016-03-31 Jayendrakumar Dasharathlal PATEL Pharmaceutical abuse deterrent composition
CA2970065A1 (en) * 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
EP3210596A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
JP7521897B2 (en) * 2017-03-31 2024-07-24 アキュラ・ファーマシューティカルズ・インコーポレーテッド Methods and compositions for the self-controlled release of active pharmaceutical ingredients - Patents.com
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
AU2018288071A1 (en) * 2017-06-23 2020-02-06 Sun Pharma Advanced Research Company Limited Abuse deterrent oral solid dosage form
JP7370125B2 (en) * 2018-11-09 2023-10-27 日本化薬株式会社 Pharmaceutical tablets containing erlotinib as the active ingredient
JP7370126B2 (en) * 2018-11-27 2023-10-27 日本化薬株式会社 Pharmaceutical tablets containing erlotinib as the active ingredient
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CN117500923A (en) 2021-04-07 2024-02-02 巴特尔纪念研究院 Rapid design, construction, testing and learning techniques for identification and use of non-viral vectors

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3260646A (en) 1962-10-19 1966-07-12 Ferring Ab Medication with mechanism to prevent overdosage
GB1428361A (en) 1972-02-15 1976-03-17 Grant A Safeguarded medicinal compositions
DE2530563C2 (en) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgesic drugs with reduced potential for abuse
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4459278A (en) 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
JPS59193831A (en) * 1983-04-18 1984-11-02 Sankyo Co Ltd Preparation of enteric drug
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4666705A (en) 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4800083A (en) * 1986-10-20 1989-01-24 R. P. Scherer Corporation Sustained release method and product
US4801461A (en) 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4915952A (en) 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US5073380A (en) 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5114942A (en) 1989-03-31 1992-05-19 Yale University Treating habit disorders
US5059600A (en) 1989-03-31 1991-10-22 Yale University Treating habit disorders
US5084278A (en) 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5284662A (en) 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5098715A (en) 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5405617A (en) 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5431916A (en) 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
US5484606A (en) 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
BR9507909A (en) 1994-06-03 1997-08-12 Procter & Gamble Quickly dissolving dosage forms
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5660859A (en) 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
NZ280610A (en) 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5556879A (en) 1995-03-01 1996-09-17 Rhone Merieux, Inc. Aqueous spectinomycin borate solutions
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5807579A (en) 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
DK0894010T3 (en) 1996-04-10 2003-10-27 Warner Lambert Co Denaturing agents for sympathomimetic amine salts
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
DK1014941T3 (en) 1996-06-26 2009-07-27 Univ Texas Extrudable pharmaceutical hot-melt formulation
US6024980A (en) 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
US5919481A (en) 1996-06-28 1999-07-06 Ncneil-Ppc, Inc. Fill material for soft gelatin pharmaceutical dosage form
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6027746A (en) 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
JP3950175B2 (en) 1997-05-30 2007-07-25 オスモティカ・コーポレイション Multi-layer penetrating device
US6153621A (en) 1997-06-23 2000-11-28 The University Of Kentucky Research Foundation Combined antagonist compositions
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
DE19740983A1 (en) 1997-09-18 1999-04-08 Warner Lambert Co N D Ges D St Solid oral formulation based on ephedrine and similar compounds containing fats or gel forming agents and surfactants making isolation difficult
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
KR100417490B1 (en) 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 A method of preventing abuse of opioid dosage forms
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
ES2277682T3 (en) 1998-06-11 2007-07-16 PHARMACIA & UPJOHN COMPANY LLC FORMULATION OF DELAVIRDINE IN COMPRESSED.
ATE311928T1 (en) 1998-07-01 2005-12-15 Warner Lambert Co (-)-PSEUDOEPHEDRINE AS A SYMPATHOMIMETIC DRUG
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GT199900148A (en) 1998-09-10 2001-02-28 Denaturing for the sympathomimetic amine salts.
SE9803239D0 (en) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (en) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
AU1937700A (en) 1998-12-15 2000-07-03 Wm. Wrigley Jr. Company Controlling release of active agents from a chewing gum coating
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030170181A1 (en) 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6340471B1 (en) 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6613357B2 (en) 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6277409B1 (en) 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
DE10010524C2 (en) * 2000-03-07 2002-08-29 Freudenberg Carl Kg Scraper with integrated seal
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
EP1312381A4 (en) * 2000-06-21 2004-12-22 Otsuka Pharma Co Ltd PREPARATIONS FOR MEASURING GASTRIC pH VALUE AND METHOD OF MEASURING GASTRIC pH VALUE BY USING THE SAME
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US20100010101A1 (en) 2000-07-05 2010-01-14 Capricorn Pharma, Inc. Rapid-Melt Compositions and Methods of Making Same
US20020022057A1 (en) 2000-08-17 2002-02-21 Battey Alyce S. Oral delivery of pharmaceuticals via encapsulation
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20020119196A1 (en) 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
US6800668B1 (en) 2001-01-19 2004-10-05 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
US6559159B2 (en) 2001-02-01 2003-05-06 Research Triangle Institute Kappa opioid receptor ligands
ATE330586T1 (en) 2001-03-14 2006-07-15 Pfizer Prod Inc PHARMACEUTICAL TABLET AND METHOD FOR PRODUCING THE SAME
UA81224C2 (en) 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20030004177A1 (en) 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
CA2447693A1 (en) 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
WO2003013481A1 (en) 2001-08-03 2003-02-20 Bakulesh Mafatlal Khamar The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
EP1429728A1 (en) 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
JP2005523876A (en) 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー Opioid formulations with reduced potential for abuse
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
CA2764642A1 (en) 2001-10-22 2003-05-01 Taro Pharmaceutical Industries Ltd. Taste masking spill-resistant formulation
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030125347A1 (en) 2001-11-02 2003-07-03 Elan Corporation Plc Pharmaceutical composition
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
KR100540035B1 (en) 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
GB2398005B (en) 2002-02-20 2005-09-14 Strides Arcolab Ltd Orally administrable pharmaceutical formulation
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7708771B2 (en) 2002-02-26 2010-05-04 Endovascular Technologies, Inc. Endovascular graft device and methods for attaching components thereof
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
WO2003101431A1 (en) 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003272069A1 (en) 2002-06-26 2004-01-19 Cadila Healthcare Limited Novel floating dosage form
AU2003272601B2 (en) 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US20040081695A1 (en) 2002-09-28 2004-04-29 Sowden Harry S Dosage forms having an inner core and an outer shell
PT1558935E (en) 2002-10-25 2008-10-16 Labopharm Inc Controlled-release compositions
DE10250084A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Dosage form protected against abuse
AU2002340694B2 (en) 2002-11-13 2006-09-21 Synthes Gmbh Articular facet interference screw
EP1603593A4 (en) 2002-11-15 2007-08-01 Branded Products For The Futur Pharmaceutical composition
US20040109889A1 (en) 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US8293799B2 (en) 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
ATE454886T1 (en) 2003-03-26 2010-01-15 Egalet As MATRIX PREPARATIONS FOR THE CONTROLLED PRESENTATION OF MEDICINAL MEDICINAL PRODUCTS
CN1819819B (en) 2003-05-07 2011-03-09 株式会社三养社 Highly plastic granules for making fast melting tablets
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20040265372A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
BRPI0413353A (en) 2003-08-06 2006-10-10 Nirmal Mulye pharmaceutical composition containing water soluble drug
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102004020220A1 (en) 2004-04-22 2005-11-10 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
JP2007502823A (en) 2003-08-15 2007-02-15 キューエルティー・ユーエスエイ・インコーポレーテッド Adhesive and bioerodible transmucosal drug delivery systems
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
CA2564962C (en) 2004-05-21 2013-08-06 Lawrence Solomon Pharmaceutical tablets comprising two or more unitary segments
US20080287456A1 (en) 2004-05-28 2008-11-20 Imaginot Pty Ltd Oral Therapeutic Compound Delivery System
US7045425B2 (en) 2004-06-30 2006-05-16 Texas Instruments Incorporated Bird's beak-less or STI-less OTP EPROM
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006017159A1 (en) 2004-07-09 2006-02-16 Drugtech Corporation Controlled phase composition technology as an improved process for protection of drugs
AU2005264159A1 (en) 2004-07-19 2006-01-26 Elutex Ltd. Modified conductive surfaces having active substances attached thereto
US20060018837A1 (en) 2004-07-26 2006-01-26 Victory Pharma, Inc. Pharmaceutical compositions and methods for the prevention of drug misuse
US20060093631A1 (en) 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
CN101212953A (en) 2005-03-29 2008-07-02 麦克内尔-Ppc股份有限公司 Compositions with hydrophilic drugs in a hydrophobic medium
WO2007052289A2 (en) 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
JP5000664B2 (en) 2005-12-08 2012-08-15 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ System and method for enabling selection of image record conversion
US20070134493A1 (en) 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
FR2898056B1 (en) 2006-03-01 2012-01-20 Ethypharm Sa SQUEEZE-RESISTANT TABLETS TO PREVENT UNLAWFUL MISUSE
US8062667B2 (en) 2006-03-16 2011-11-22 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
CN101460150B (en) 2006-03-31 2014-02-12 鲁比康研究私人有限公司 Directly compressible composite for orally disintegrating tablets
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AU2007261098A1 (en) 2006-06-19 2007-12-27 Mcneil-Ppc, Inc. Enteric coated particles containing an active ingredient
US20080095843A1 (en) 2006-07-11 2008-04-24 Nutalapati Siva R K Controlled-release formulations
EP2043613A1 (en) 2006-07-14 2009-04-08 Fmc Corporation Solid form
US20080075770A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic abuse deterrent delivery system
EP2049548A1 (en) * 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
CA2661172A1 (en) 2006-09-04 2008-05-29 Panacea Biotec Limited Programmable buoyant delivery technology
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
MX2009011973A (en) 2007-05-08 2009-12-10 Hercules Inc Robust rapid disintegration tablet formulation.
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
EP2167049B1 (en) 2007-06-04 2016-08-31 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US9254268B2 (en) 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US20090081291A1 (en) 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
EP2205213A2 (en) 2007-10-01 2010-07-14 Laboratorios Lesvi, S.L. Orodispersible tablets
WO2009066146A2 (en) 2007-11-19 2009-05-28 Cadila Pharmaceuticals Ltd. Stable solutions of sparingly soluble actives
JP5651818B2 (en) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド Controlled release formulation to prevent misuse
EP2229156B1 (en) 2007-12-20 2016-11-09 Fertin Pharma A/S Chewing gum tablet and method of dosing pharmaceutically active ingredients in such chewing gum tablet
DK2229158T3 (en) 2007-12-20 2016-12-12 Fertin Pharma As Compressed chewing gum tablet
EP2229157B1 (en) 2007-12-20 2016-08-10 Fertin Pharma A/S Compressed chewing gum tablet
CN101951891A (en) 2008-01-11 2011-01-19 希普拉有限公司 Solid pharmaceutical dosage form
CN102014877B (en) 2008-01-25 2017-06-06 格吕伦塔尔有限公司 Pharmaceutical dosage form
WO2009122431A2 (en) 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet
US8420700B1 (en) 2008-06-04 2013-04-16 James M. Bausch Tamper resistant lipid-based oral dosage form for sympathomimetic amines
WO2010038691A1 (en) * 2008-09-30 2010-04-08 アステラス製薬株式会社 Particulate pharmaceutical composition for oral administration
WO2010044736A1 (en) 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
SE533001C2 (en) 2008-10-17 2010-06-08 Scania Cv Abp A connection device
EP2198859A1 (en) 2008-12-17 2010-06-23 Losan Pharma GmbH Melt-coated pharmaceutical composition with fast release
US9622972B2 (en) * 2009-03-04 2017-04-18 Emplicure Ab Abuse resistant formula
US20100260842A1 (en) 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
US9572781B2 (en) * 2009-05-01 2017-02-21 Adare Pharmaceuticals, Inc. Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics
WO2010139111A1 (en) * 2009-06-02 2010-12-09 Dow Global Technologies Inc. Sustained release dosage form
MX2012003082A (en) 2009-09-17 2012-04-19 Cadila Healthcare Ltd Pharmaceutical compositions for reducing alcohol-induced dose dumping.
CA2775890C (en) 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011066980A2 (en) * 2009-12-04 2011-06-09 Lars Holger Hermann Oral dosage forms with reduced potential for drug abuse
WO2011079074A1 (en) * 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
WO2011121824A1 (en) * 2010-03-29 2011-10-06 アステラス製薬株式会社 Orally disintegrating tablet
EP2635258A1 (en) * 2010-11-04 2013-09-11 AbbVie Inc. Drug formulations
MX366159B (en) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Self-regulated release of active pharmaceutical ingredient.
ES2764445T3 (en) * 2013-03-15 2020-06-03 Inspirion Delivery Sciences Llc Pharmaceutical products comprising a pH dependent component and a pH increasing agent
CN205269008U (en) * 2013-05-06 2016-06-01 未来动力公司 Electronic vehicle of electronic vehicle , electric skate board and self -balancing
US10083794B2 (en) * 2015-05-11 2018-09-25 Panasonic Intellectual Property Management Co., Ltd. Metallized film capacitor

Also Published As

Publication number Publication date
CN107595793B (en) 2020-11-13
AU2023200124A1 (en) 2023-02-09
AU2020210206A1 (en) 2020-08-20
CN104968333B (en) 2018-07-10
WO2014085599A1 (en) 2014-06-05
CA2892908C (en) 2016-04-12
US20140155388A1 (en) 2014-06-05
AU2013352162A1 (en) 2015-05-28
US20150374821A1 (en) 2015-12-31
US9101636B2 (en) 2015-08-11
US20160199388A1 (en) 2016-07-14
JP2016501231A (en) 2016-01-18
US11857629B2 (en) 2024-01-02
IL238713A0 (en) 2015-06-30
JP6974378B2 (en) 2021-12-01
JP6027283B2 (en) 2016-11-16
EP2925304A4 (en) 2016-05-11
US20200376123A1 (en) 2020-12-03
AU2018260929A1 (en) 2018-11-29
AU2013352162B2 (en) 2018-08-16
CN108743549B (en) 2024-08-06
CN107595793A (en) 2018-01-19
EP2925304B1 (en) 2018-09-05
JP2019112441A (en) 2019-07-11
CN104968333A (en) 2015-10-07
CN108743549A (en) 2018-11-06
EP2925304A1 (en) 2015-10-07
JP2018070657A (en) 2018-05-10
RU2015124694A (en) 2017-01-10
AU2020210206B2 (en) 2022-10-13
US20170239354A1 (en) 2017-08-24
MX2019007956A (en) 2019-09-04
US10688184B2 (en) 2020-06-23
US20210330793A1 (en) 2021-10-28
ES2691982T3 (en) 2018-11-29
US11083794B2 (en) 2021-08-10
JP2017036315A (en) 2017-02-16
RU2018141241A3 (en) 2021-11-16
US20180326065A1 (en) 2018-11-15
US10441657B2 (en) 2019-10-15
AU2018260929B2 (en) 2020-04-30
JP2023175780A (en) 2023-12-12
JP6272434B2 (en) 2018-01-31
CA2892908A1 (en) 2014-06-05
RU2018141241A (en) 2019-01-24
MX2015006613A (en) 2015-11-16
EP3446685A1 (en) 2019-02-27
JP2016166225A (en) 2016-09-15
US20240108726A1 (en) 2024-04-04
US9662393B2 (en) 2017-05-30
RU2673818C2 (en) 2018-11-30
US9320796B2 (en) 2016-04-26
JP2022025125A (en) 2022-02-09
JP5922851B2 (en) 2016-05-24

Similar Documents

Publication Publication Date Title
MX2019007956A (en) Self-regulated release of active pharmaceutical ingredient.
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
IN2015DN03984A (en)
GB2495676A (en) Use of binders for manufacturing storage stable formulations
WO2012034079A3 (en) Macrolide dosage forms
EP2832851A4 (en) Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient
IN2014MN01706A (en)
EA201400737A1 (en) DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE
MX347105B (en) Pharmaceutical compositions comprising hydromorphone and naloxone.
MX2016003754A (en) A stable pharmaceutical composition containing amlodipine and valsartan.
TN2014000001A1 (en) A new therapeutical composition containing apomorphine as active ingredient
MX2019008817A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof.
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
WO2012023024A3 (en) Controlled release formulations of dronedarone
PH12015500374A1 (en) Extended release compositions of an aminoalkyl nitrate
PH12014502836A1 (en) Medicament form for release of active ingredients
MX2014006201A (en) Imatinib solid dosage forms reconstituted just before use.
UA109944U (en) PHARMACEUTICAL COMPOSITION TO REDUCE THE N-OXIDE OF TRIMETHYLAMINE LEVEL
EP2842938A4 (en) Novel beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
IN2012CH05549A (en)
IN2014CN04119A (en)
WO2013057569A3 (en) Extended release pharmaceutical composition containing amoxicillin and clavulanic acid

Legal Events

Date Code Title Description
FG Grant or registration